FLUEQUIN H, emulsion for injection for horses

New vaccine for the active immunization of horses to reduce the incidence of respiratory infections and clinical symptoms caused by influenza virus and equine herpesvirus horses (EHV-1)

• Contains current strain EHV-1 isolated in the Czech Republic, which also provides cross immunity against EHV-4
• Includes new strains of influenza viruses in accordance with the recommendations of the OIE
• Excellent tolerability and low application rate 1 ml intramuscular injection
• Packing: 2x1 dose,  10x1 dose

One dose (1 ml) of the vaccine contains:

Active substances:

Inactivated virus equine influenza, strain:

A/Equi 2 Morava 95    -     Min. 6.0 log₂ HIT¹

A/Equi 2 Brno 08        -     Min. 6.0 log₂ HIT¹

Inactivated equine herpes virus (EHV-1)      -       Min. 2.1 log₁₀ VNI²

1  geometrical average of specific antibodies determinated by heamagglutination inhibition test in serum of guinea pigs

2  Virus neutralization index determined in serum of  hamsters

Adjuvant(s): Oil adjuvans (Montanide ISA 35 VG)   -  0.25 ml

Excipient(s): Thiomersal   -  0.1 mg

INDICATION(S)

For the active immunization of horses to reduce the incidence of respiratory infections and clinical symptoms caused by influenza virus and equine herpesvirus horses (EHV-1).

Onset of Immunity: 14 days after primary vaccination

Duration of Immunity: 6 months after revaccination

For the active immunization of pregnant mares to reduce the incidence of abortion induced herpes virus infection of horses (EHV-1).

TARGET SPECIES

Horses

DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

The vaccination dose – 1 ml

The vaccine (1 ml) is applied deep intramuscularly into the neck muscle; it is applied into the pectoral muscle only exceptionally in case of restless horses.

Primary vacciantionagainst influenza and equine herpes virus:

1st vaccination at the age of 6 months; 2nd vaccination after 4 weeks;

Revaccinationagainst influenza and equine herpes virus:

The first revaccination (third dose) should be administered  3 months after primary vaccination and each following revaccination is applied every six months.

Vaccination pregnant mares:

To reduce the incidence of abortion caused by equine herpesvirus infection is administered 1 dose of the vaccine in pregnant mares in the second month after admission and at 5 to 6th and the 9th month of pregnancy.

ADVICE ON CORRECT ADMINISTRATION

Before use, the contents of the vial warm up a temperature of 15-25 ° C and the content of the vial shaken well

WITHDRAWAL PERIOD

Zero days

SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.  Store in a refrigerator (2 °C – 8 °C)

Protect from light. Store in a dry place.  Shelf-life after first opening the container: 10 hours

PACKAGE

 2 x 1 doses, 10 x 1 doses